The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Arm ...

A drug trial failure this spring has had no impact on the market for one of Bristol Myers Squibb’s most closely-watched new ...

Bristol-Myers Squibb (BMY) shares rise after beating Q2 forecasts, raising 2025 revenue outlook, and showcasing growth in key ...

Bristol Myers Squibb surpassed analyst expectations with a strong Q2, as notable brands Eliquis, Opdivo, and Revlimid drove ...

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

Bristol Myers Squibb outperformed expectations in the second quarter, with boosted sales from key brands Eliquis, Opdivo, and ...

A global biotech is axing more of its Greater Washington workforce, eliminating nearly 100 positions across multiple waves of ...

MAINZ, Germany, November 4, 2024-- BioNTech SE today reported financial results for the three and nine months ended September 30, 2024 and provided an update on its corporate progress. Ugur Sahin ...

New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a final ...